Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Flow Pharma Forms JV with Button Capital for China Clinical Trials

publication date: Sep 26, 2018

Flow Pharma, a San Francisco Bay Area biotech, has formed a China JV with Button Capital to conduct China clinical trials of its therapeutic cancer vaccines. Button is a Silicon Valley-based investor that supports companies around the globe. Flow uses artificial intelligence to select neoantigen peptide targets on cancer cells or virus-infected cells, which are then targeted by the patient's own immune system. The peptides are loaded into the FlowVax synthetic therapeutic vaccine platform. The company's initial product is a pre-clinical HPV vaccine to treat cervical cancer. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital